SEC Form 4 · accession 0001209191-18-041384
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Rosen
Officer — President · Director
Period of report
Jun 29, 2018
Accepted (ET)
Jul 3, 2018 · 9:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818033
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2018 | M | 129,469 | $7.20 | A | 132,109 | D | |
| Common StockF2 | Jun 29, 2018 | S | 75,661 | $39.1367 | D | 56,448 | D | |
| Common StockF3 | Jun 29, 2018 | S | 51,696 | $40.1694 | D | 4,752 | D | |
| Common StockF4 | Jun 29, 2018 | S | 2,112 | $41.3899 | D | 2,640 | D | |
| Common Stock | Jul 2, 2018 | M | 95,531 | $7.20 | A | 98,171 | D | |
| Common StockF5 | Jul 2, 2018 | S | 92,131 | $38.1296 | D | 6,040 | D | |
| Common StockF6 | Jul 2, 2018 | S | 3,400 | $38.7544 | D | 2,640 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F7 | $7.20 | Jun 29, 2018 | M | 129,469 | D | — | May 1, 2023 | Common Stock | 129,469 | 695,531 | D |
| Employee Stock Option (Right to Buy)F7 | $7.20 | Jul 2, 2018 | M | 95,531 | D | — | May 1, 2023 | Common Stock | 95,531 | 600,000 | D |
Explanation of responses
- F1The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018.
- F2The range of sales prices received was $38.75 to $39.75. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F3The range of sales prices received was $39.775 to $40.70. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F4The range of sales prices received was $41.075 to $41.45. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F5The range of sales prices received was $37.50 to $38.50. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F6The range of sales prices received was $38.55 to $38.85. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F7At the date of filing, 412,500 shares of the options granted pursuant to the underlying awards were fully vested and exercisable.